Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM)

British Journal of Haematology

Volumn 92, Issue 2, 1996, Pages 420-422

  Kyrstsonis, Maria Christina ^b   Dedoussis, Georges ^a   Baxevanis, Constantin ^a   Stamatelou, Marina ^a   Maniatis, Alice ^b  

^a Department of Cytology   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Interleukin 4; Interleukin 6; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; INTERLEUKIN 4; INTERLEUKIN 6; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0030052779     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1491.x     Document Type: Article

References (11)

1. Bataille, R., Jourdan, M., Zhang, X-G. & Klein, B. (1989) Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
2. Defrance, T., Fluckiger, A-C., Rossi, J-F., Magaud, J-P., Sotto, J-J. & Banchereau, J. (1992) Antiproliferative effects of inlerleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. Blood, 79, 990-996.
3. Hermann, F., Andreeff, M., Grass, H-J., Bach, M.A., Lubbert, M. & Mertelsmann, R. (1991) Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood, 78, 2070-2074.
4. Klein, B. & Brailly, H. (1995) Cytokine-binding proteins: stimulating antagonists. Immunology Today, 16, 216-220.
5. Klein, B., Zhang, X-G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) A paracrine but not autocrine regulation of plasma cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
6. Klein, B., Zhang, X-E., Lu, Z-Y. & Bataille, R. (1995) Interleukin-6 in human multiple myeloma. Blood, 85, 863-872.
7. Pelliniemi, T.T., Irjala, K., Mattila, K., Pulkki, K., Rajamaki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood, 85, 765-771.
8. San Miguel, J.F., Gonzalez, M., Gascon, A., Moro, M.J., Hernandez, J.M., Ortega, F., Jimenez, R., Guerras, L., Romero, M. Casanova, F., Sanz, M.A., Sanchez, J., Portera, J.A. & Orfao, A. (1992) Lymphoid subsets and prognostic factors in multiple myeloma. British Journal of Haematology, 80, 305-309.
9. Taylor, C.W., Grogan, T.M. & Salmon, S.E. (1990) Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood, 75, 1114-1118.
10. Tienhaara, A., Pulkki, K., Mattila, K., Kerttu, I. & Pelliniemi, T-T. (1994) Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. British Journal of Haematology, 86, 391-395.
11. Vesole, D., Kornbluth, J., Jagannath, S., Mattox, S., Vaugt, L., Tricot, G. & Barlogie, B. (1993) Biological response modifiers (BRM) in refractory multiple myeloma (MM): lack of clinical efficacy of recombinant human interleukin-4 (rhIL-4) and all-trans retinoic acid (ATRA). Blood, 10, (Suppl. 1), 263a, no. 1037.